Company intelligence / Profile preview

AxImmune

Fort Collins, Colorado, United States

Ownership: Private
Development stage: Other

Overview

AxImmune is developing Ax-101, a small molecule immuno-oncology drug shown in preclinical and limited human studies to have potent anti-tumor activity, both as monotherapy and synergistically with immune checkpoint inhibitors. No significant drug-related adverse effects were observed in early trials. The company aims to expand patient response to checkpoint therapies.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

AX-101

Unknown

Partnerships

Colorado State UniversityAxon Connected, LLC

Beyond the preview

Go deeper on AxImmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AxImmune.

Explore the full profile